Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 3
1982 1
1984 1
1985 2
1986 1
1987 10
1988 4
1989 6
1990 4
1991 9
1992 9
1993 8
1994 9
1995 5
1996 7
1997 9
1998 12
1999 18
2000 14
2001 9
2002 11
2003 10
2004 13
2005 12
2006 7
2007 17
2008 13
2009 7
2010 14
2011 4
2012 10
2013 13
2014 15
2015 19
2016 27
2017 47
2018 39
2019 36
2020 43
2021 53
2022 43
2023 30
2024 35
2025 14

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

617 results

Results by year

Filters applied: . Clear all
Page 1
Trends in the approval of cancer therapies by the FDA in the twenty-first century.
Scott EC, Baines AC, Gong Y, Moore R Jr, Pamuk GE, Saber H, Subedee A, Thompson MD, Xiao W, Pazdur R, Rao VA, Schneider J, Beaver JA. Scott EC, et al. Among authors: pazdur r. Nat Rev Drug Discov. 2023 Aug;22(8):625-640. doi: 10.1038/s41573-023-00723-4. Epub 2023 Jun 21. Nat Rev Drug Discov. 2023. PMID: 37344568 Review.
Improving Dose-Optimization Processes Used in Oncology Drug Development to Minimize Toxicity and Maximize Benefit to Patients.
Fourie Zirkelbach J, Shah M, Vallejo J, Cheng J, Ayyoub A, Liu J, Hudson R, Sridhara R, Ison G, Amiri-Kordestani L, Tang S, Gwise T, Rahman A, Pazdur R, Theoret MR. Fourie Zirkelbach J, et al. Among authors: pazdur r. J Clin Oncol. 2022 Oct 20;40(30):3489-3500. doi: 10.1200/JCO.22.00371. Epub 2022 Sep 12. J Clin Oncol. 2022. PMID: 36095296 Review.
The Drug-Dosing Conundrum in Oncology - When Less Is More.
Shah M, Rahman A, Theoret MR, Pazdur R. Shah M, et al. Among authors: pazdur r. N Engl J Med. 2021 Oct 14;385(16):1445-1447. doi: 10.1056/NEJMp2109826. Epub 2021 Oct 9. N Engl J Med. 2021. PMID: 34623789 No abstract available.
FDA Approval Summary: Mirvetuximab Soravtansine-Gynx for FRα-Positive, Platinum-Resistant Ovarian Cancer.
Dilawari A, Shah M, Ison G, Gittleman H, Fiero MH, Shah A, Hamed SS, Qiu J, Yu J, Manheng W, Ricks TK, Pragani R, Arudchandran A, Patel P, Zaman S, Roy A, Kalavar S, Ghosh S, Pierce WF, Rahman NA, Tang S, Mixter BD, Kluetz PG, Pazdur R, Amiri-Kordestani L. Dilawari A, et al. Among authors: pazdur r. Clin Cancer Res. 2023 Oct 2;29(19):3835-3840. doi: 10.1158/1078-0432.CCR-23-0991. Clin Cancer Res. 2023. PMID: 37212825 Free PMC article.
FDA Approval Summary: Alpelisib for PIK3CA-Related Overgrowth Spectrum.
Singh S, Bradford D, Li X, Mishra-Kalyani PS, Shen YL, Wang L, Zhao H, Xiong Y, Liu J, Charlab R, Kraft J, Khasar S, Miller CP, Rivera DR, Kluetz PG, Pazdur R, Beaver JA, Singh H, Donoghue M. Singh S, et al. Among authors: pazdur r. Clin Cancer Res. 2024 Jan 5;30(1):23-28. doi: 10.1158/1078-0432.CCR-23-1270. Clin Cancer Res. 2024. PMID: 37624421 Free PMC article.
Docetaxel.
Cortes JE, Pazdur R. Cortes JE, et al. Among authors: pazdur r. J Clin Oncol. 1995 Oct;13(10):2643-55. doi: 10.1200/JCO.1995.13.10.2643. J Clin Oncol. 1995. PMID: 7595719 Review.
FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer.
Fallah J, Agrawal S, Gittleman H, Fiero MH, Subramaniam S, John C, Chen W, Ricks TK, Niu G, Fotenos A, Wang M, Chiang K, Pierce WF, Suzman DL, Tang S, Pazdur R, Amiri-Kordestani L, Ibrahim A, Kluetz PG. Fallah J, et al. Among authors: pazdur r. Clin Cancer Res. 2023 May 1;29(9):1651-1657. doi: 10.1158/1078-0432.CCR-22-2875. Clin Cancer Res. 2023. PMID: 36469000 Free PMC article. Clinical Trial.
Overall Survival and the Evolving Benefit-Risk Assessment for Poly (ADP-ribose) Polymerase Inhibitors in Advanced Ovarian Cancer.
Shah M, Chen TY, Ison G, Fiero MH, Zhang H, Gao X, Neilson M, Goldberg KB, Nair A, Ricks TK, Pierce WF, Gormley N, Theoret MR, Tang S, Pazdur R, Kluetz PG, Amiri-Kordestani L. Shah M, et al. Among authors: pazdur r. J Clin Oncol. 2025 Jul;43(19):2218-2227. doi: 10.1200/JCO-24-02834. Epub 2025 May 19. J Clin Oncol. 2025. PMID: 40388682 Review.
FDA Approval Summary: Ivosidenib in Combination with Azacitidine for Treatment of Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation.
Woods A, Norsworthy KJ, Wang X, Vallejo J, Chiu Yuen Chow E, Li RJ, Sun J, Charlab R, Jiang X, Pazdur R, Theoret MR, de Claro RA. Woods A, et al. Among authors: pazdur r. Clin Cancer Res. 2024 Apr 1;30(7):1226-1231. doi: 10.1158/1078-0432.CCR-23-2234. Clin Cancer Res. 2024. PMID: 38010220 Free PMC article. Clinical Trial.
617 results